Ultrasound reveals hidden stomach risks in semaglutide users
NCT ID NCT06292065
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study used bedside ultrasound to see if people taking semaglutide (Ozempic, Wegovy) have more food or liquid in their stomachs before surgery, despite fasting. Researchers compared 88 adults on semaglutide to those not taking it. The goal was to help anesthesiologists decide if it's safe to proceed with anesthesia or if changes are needed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- semaglutide
- What this could lead to
- If successful, this could help doctors make safer anesthesia decisions for patients on semaglutide by better predicting stomach fullness.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
88 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria for the semaglutide cohort are: * Adults (\>=18 years old) * Semaglutide therapy for any indication (type 2 diabetes or weight loss) * Semaglutide therapy at any dose * Semaglutide therapy with any route of administration * Semaglutide therapy administered daily or weekly * Semaglutide therapy at any time since initiation * Elective surgery of any kind for which general anaesthesia was planned preoperatively * Adherence to current ASA recommendation regarding GLP-1-RA; i.e. holding semaglutide for 1 week if administered weekly or for 1 day if administered daily. * Adherence to current ESAIC fasting guidelines; i.e. \>2 hours for liquids and \>6 hours for solid foods. Inclusion criteria for the control cohort are: * Adults (\>=18 years old) * Elective surgery of any kind for which general anaesthesia was planned preoperatively * Adherence to current ESAIC fasting guidelines; i.e. \>2 hours for liquids and \>6 hours for solid foods Exclusion criteria for the semaglutide cohort are: * Semaglutide not held in accordance with current ASA recommendation, i.e. held either longer or shorter than recommended. * No adherence to current ESAIC fasting guideline * Presence of a contra-indication to gastric ultrasound; i.e. previous gastric surgery (e.g. partial gastrectomy, gastric bypass) or hiatal hernias. * Presence of comorbidities associated with delayed gastric emptying: scleroderma, systemic lupus erythematosus, hypothyroidism, Parkinson disease, cerebral palsy, and multiple sclerosis. * Inability to assume the right lateral decubitus position * Initial anaesthetic plan did not involve general anaesthesia, e.g. neuraxial or locoregional cases Exclusion criteria for the control cohort are: * Semaglutide or other GLP-1-RA therapy * No adherence to current ESAIC fasting guideline * Presence of a contra-indication to gastric ultrasound; i.e. previous gastric surgery (e.g. partial gastrectomy, gastric bypass) or hiatal hernias * Presence of comorbidities associated with delayed gastric emptying: scleroderma, systemic lupus erythematosus, hypothyroidism, Parkinson disease, cerebral palsy, and multiple sclerosis * Inability to assume the right lateral decubitus position * Initial anaesthetic plan does not involve general anaesthesia, e.g. locoregional cases
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastroparesis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antwerp University Hospital
Edegem, Antwerp, 2650, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound could reveal when ICU tube feeding fails
- Stomach sensor may unmask hidden effects of weight-loss drugs
- A sticker-based stomach scan may replace radioactive tests for a chronic digestive disorder
- Can a stomach muscle cut tame diabetes blood sugar?
- Could a skin patch ease stomach pain in scleroderma?
- Could a botox shot in the gut ease Kids' chronic vomiting?